Patricia A Cioe1, Alana N Mercurio2, William Lechner3, Catherine C Costantino2, Jennifer W Tidey2, Thomas Eissenberg4, Christopher W Kahler2. 1. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA. Electronic address: Patricia_Cioe@brown.edu. 2. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, USA. 3. Department of Psychological Sciences, Kent State University, Kent, OH, USA. 4. Department of Psychology and Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, VA, USA.
Abstract
INTRODUCTION: Some HIV-positive smokers report ambivalence about quitting. Switching to electronic cigarettes (ECs) may be a viable option to reduce the negative health effects for smokers who are unable or unwilling to quit smoking combustible cigarettes (CCs). This study examined the acceptability and health-related effects of ECs in HIV-positive smokers who were not seeking smoking cessation treatment. METHODS: HIV-positive smokers (N = 19) were enrolled and followed for 12 weeks. Cartridge-based ECs were provided at baseline, and E-liquid was provided weekly for 8 weeks. At baseline, weeks 1-8, and week 12, EC and CC use, cardiopulmonary function, respiratory symptoms, and carbon monoxide (CO) levels were measured. RESULTS: At week 8, cigarettes per day (CPD) were reduced by more than 80%, with reduction maintained at week 12 (p's < .001). Cigarette dependence scores were 40% lower at week 8 than at baseline (p < .001). Seven (36.8%) participants reported transitioning completely from CCs to ECs. Mean CO decreased significantly from BL to week 8 (p < .05) and remained significantly lower at week 12 (p < .001). Intention to quit increased significantly over time. CONCLUSIONS: Switching from CCs to ECs in HIV-positive smokers who are not ready to quit smoking in the next 30 days appears to be feasible. Beneficial effects were seen, such as reduced CPD, reduced CO and CC dependence, and increased motivation to quit. ECs may be promising as a harm reduction approach among HIV-positive smokers who are unable or unwilling to quit smoking.
INTRODUCTION: Some HIV-positive smokers report ambivalence about quitting. Switching to electronic cigarettes (ECs) may be a viable option to reduce the negative health effects for smokers who are unable or unwilling to quit smoking combustible cigarettes (CCs). This study examined the acceptability and health-related effects of ECs in HIV-positive smokers who were not seeking smoking cessation treatment. METHODS: HIV-positive smokers (N = 19) were enrolled and followed for 12 weeks. Cartridge-based ECs were provided at baseline, and E-liquid was provided weekly for 8 weeks. At baseline, weeks 1-8, and week 12, EC and CC use, cardiopulmonary function, respiratory symptoms, and carbon monoxide (CO) levels were measured. RESULTS: At week 8, cigarettes per day (CPD) were reduced by more than 80%, with reduction maintained at week 12 (p's < .001). Cigarette dependence scores were 40% lower at week 8 than at baseline (p < .001). Seven (36.8%) participants reported transitioning completely from CCs to ECs. Mean CO decreased significantly from BL to week 8 (p < .05) and remained significantly lower at week 12 (p < .001). Intention to quit increased significantly over time. CONCLUSIONS: Switching from CCs to ECs in HIV-positive smokers who are not ready to quit smoking in the next 30 days appears to be feasible. Beneficial effects were seen, such as reduced CPD, reduced CO and CC dependence, and increased motivation to quit. ECs may be promising as a harm reduction approach among HIV-positive smokers who are unable or unwilling to quit smoking.
Authors: Blair N Coleman; Brian Rostron; Sarah E Johnson; Bridget K Ambrose; Jennifer Pearson; Cassandra A Stanton; Baoguang Wang; Cristine Delnevo; Maansi Bansal-Travers; Heather L Kimmel; Maciej L Goniewicz; Raymond Niaura; David Abrams; Kevin P Conway; Nicolette Borek; Wilson M Compton; Andrew Hyland Journal: Tob Control Date: 2017-06-17 Impact factor: 7.552
Authors: I Mark Olfert; Evan DeVallance; Hannah Hoskinson; Kayla W Branyan; Stuart Clayton; Christopher R Pitzer; D Patrick Sullivan; Matthew J Breit; Zhongxin Wu; Powsiri Klinkhachorn; W Kyle Mandler; Brett H Erdreich; Barbara S Ducatman; Randall W Bryner; Piyali Dasgupta; Paul D Chantler Journal: J Appl Physiol (1985) Date: 2017-11-02
Authors: Tuo-Yen Tseng; Paul Krebs; Antoinette Schoenthaler; Selena Wong; Scott Sherman; Mirelis Gonzalez; Antonio Urbina; Charles M Cleland; Donna Shelley Journal: AIDS Behav Date: 2017-07
Authors: Stephanie Edwards; Cheneal Puljević; Judith A Dean; Charles Gilks; Mark A Boyd; Peter Baker; Peter Watts; Chris Howard; Coral E Gartner Journal: AIDS Behav Date: 2022-07-22
Authors: Jonathan Shuter; Krishna P Reddy; Emily P Hyle; Cassandra A Stanton; Nancy A Rigotti Journal: Lancet HIV Date: 2021-08-27 Impact factor: 16.070
Authors: Philip T Diaz; Amy Ferketich; Mary E Wewers; Kristine Browning; Mikhail A Gavrilin; Anasuya Sarkar; Jennifer Hollyfield; Teresa Trinka; Mark Wewers Journal: J Acquir Immune Defic Syndr Date: 2020-12-15 Impact factor: 3.771